Maintenance therapy in multiple myeloma

Leukemia

Volumn 21, Issue 6, 2007, Pages 1150-1157

  Mihelic, R ^a   Kaufman, J L ^a   Lonial, S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ALPHA2B INTERFERON; BORTEZOMIB; CANCER VACCINE; CARMUSTINE; CD40 ANTIGEN; CNTO 328; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLUCOCORTICOID; INTERFERON; LENALIDOMIDE; MELPHALAN; MIDOSTAURIN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROTEIN ANTIBODY; QUININE; RECEPTOR BLOCKING AGENT; SCIO 469; SYNDECAN 1; THALIDOMIDE; TKI 258; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MALAISE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL TIME; THERAPY EFFECT; THROMBOSIS; TREATMENT RESPONSE; VEIN THROMBOSIS;

EID: 34249669340     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404633     Document Type: Review

References (52)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351 1860-1873.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
4. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.
5. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
6. Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H. Interferon therapy in myelomatosis. Lancet 1979; 1: 245-247.
7. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430-1434.
8. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1994; 12: 2405-2414.
9. Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A: 146-151.
10. Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, Maclennan IC. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in adults. Br J Haematol 1998; 101: 195-202.
11. Blade J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S et al. Maintenance treatment with interferon alpha-2b in multiple myeloma: A prospective randomized study from PETHEMA (Program for the Study and Treatment of Hermatological
12. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study. Cooperative Study Group. Br J Haematol 1995; 89: 561-568.
13. Pulsoni A, Avvisati G, Petrucci MT, Mandelli F, Giannarelli D, Lauta VM et al. The Italian experience on interferon as maintenance treatment in multiple myeloma: Ten years after. Blood 1998; 92 2184-2186.
14. Schaar CG, Kluin-Nelemans HC, te Marvelde C, le Cessie S, Breed WP, Fibbe WE et al. Interferon-(alphal) as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005; 16: 634-639.
15. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 2000; 65: 204-209.
16. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034.
17. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Onco1 2000; 11: 1427-1436.
18. Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130-1136.
19. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 1998; 102: 495-502.
20. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
21. McIntyre OR, Pajak TF, Kyle RA, Cornwell III GG, Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol 1985; 13: 239-243.
22. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11.
23. Friedenberg WR, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171-175.
24. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
25. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163-3168.
26. Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1998; 16: 890-896.
27. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
28. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
29. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897-901.
30. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444-4454.
31. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771.
32. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003; 40: 3-7.
33. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
34. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
35. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D. et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
36. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
37. Sahebi F, Spielberger R, Kogut NM, Fung H, Falk PM, Parker P et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 825-829.
38. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170-8176.
39. Brinker BT, Waller EK, Leong T, Heffner Jr LT, Redei I, Langston AA et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor transplantation for multiple myeloma. Cancer 2006; 106: 2171-2180.
40. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 108: 3289-3294.
41. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
42. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006; 20: 1017-1027.
43. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004; 23 8766-8776.
44. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941-2948.
45. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
46. Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M. et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004; 89: 717-741.
47. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-398.
48. Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 2006; 312: 1909-1923.
49. Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006; 12: 4908-4915.
50. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580.
51. Menu E, Jemberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MM mouse model. Blood 2006; 107: 655-660.
52. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA. Antibody targeting of the insulin-like factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007; 56; 343-357.